39 completed, 3 withdrawn, 1 active not recruiting, 1 not yet recruiting. 46 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 46 | Completed 39, Withdrawn 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 1, Terminated 1, Unknown 1 |
Follow Glycopyrrolate: new trials by email Literature Review of Glycopyrrolate trials Research Report on Glycopyrrolate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Fluticasone/Formoterol/Glycopyrronium for the Treatment Chronic Obstructive Pulmonary Disease (TRIPLAR) Fluticasone 250mcg/Formoterol 12mcg/Glycopyrronium 25mcg, Comparator - Trimbow® - Chronic Obstructive Pulmonary Disease | Phase 3 | Not yet recruiting | Eurofarma Laboratorios S.A. | 1252 | 2027-01-30 | 2026-10-26 |
| A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy Glycopyrronium, Ipratropium, Saline - Subjects Undergoing Flexible Bronchoscopy | Phase 2 / Phase 3 | Unknown | Post Graduate Institute of Medical Education and Research, Chandigarh | 1050 | 2024-04-24 | 2024-04-22 |
| A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a Next-Generation Propellant in Participants 40 to 80 Years of Age With COPD BGF MDI HFO 320/14.4/9.6μg, BGF MDI HFA 320/14.4/9.6 μg, Placebo MDI HFA - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | AstraZeneca | 297 | 2024-01-11 | 2025-08-27 |
| A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD). Treatment A : Budesonide, Glycopyrronium, and Formoterol Fumarate, Treatment B: Budesonide and Formoterol Fumarate, Treatment C : Placebo - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | AstraZeneca | 171 | 2023-10-24 | 2026-03-05 |
| A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD Beclomethasone Dipropionate, Glycopyrronium Bromide, Formoterol Fumarate - COPD, COPD Exacerbation | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 3406 | 2022-04-27 | 2026-09-21 |
| Neostigmine and Glycopyrrolate by Iontophoresis Combination of Neostigmine and Glycopyrrolate, I-Box by Dynatronics - Spinal Cord Injuries, Constipation | Phase 3 | Active not recruiting | James J. Peters Veterans Affairs Medical Center | 6 | 2020-11-06 | 2024-04-08 |
| Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery Sugammadex, Neostigmine, Glycopyrrolate - Burns | Phase 3 | Completed | University of Kansas Medical Center | 7 | 2018-03-15 | 2023-09-28 |
| RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative Indacaterol/Glycopyrrolate, Placebo - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | University of Michigan | 780 | 2017-08-29 | 2023-04-13 |
| Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease Glycopyrronium/Formoterol Fumarate, umeclidinium/vilanterol - Chronic Obstructive Pulmonary Disease COPD | Phase 3 | Completed | AstraZeneca | 1119 | 2017-05-25 | 2019-05-22 |
| Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma NVA237 (glycopyrronium bromide), Placebo - Asthma | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2017-05-04 | 2019-01-16 |
| Active Controlled Trial of CHF5993 Pressurized Metered-dose Inhaler ( pMDI) vs Symbicort®Turbuhaler® in Patients With Chronic Obstructive Pulmonary Disease ( COPD) (TRIVERSYTI) CHF 5993 100/6/12.5 µg, 160 µg budesonide + 4.5 µg formoterol fumarate - COPD (Chronic Obstructive Pulmonary Disease) | Phase 3 | Completed | Chiesi Farmaceutici S.p.A. | 708 | 2016-12-14 | 2026-07-20 |
| A Study to Compare Fluticasone /Formoterol Breath Actuated Inhaler (BAI) and Ultibro in Subjects With Fixed Airflow Obstruction and Elevated Eosinophils fluticasone propionate/formoterol fumarate breath actuated inhaler, Indacaterol maleate / glycopyrronium bromide capsules - ACOS (Fixed Airflow Obstruction and Elevated Eosinophils) | Phase 2 / Phase 3 | Terminated | Mundipharma Research Limited | 2 | 2016-07-01 | 2016-12-12 |
| Efficacy and Safety Study of QVA149 in COPD Patients QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Novartis Pharmaceuticals | 357 | 2015-07-28 | 2017-12-26 |
| Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD GFF MDI (PT003), FF MDI (PT005), GP MDI (PT001) - Chronic Obstructive Pulmonary Disease | Phase 3 | Completed | Pearl Therapeutics, Inc. | 1756 | 2015-03-30 | 2019-02-20 |
| Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma NVA237, Placebo to NVA237, salbutamol/ albuterol - Asthma | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2015-03-01 | 2015-04-13 | |
| 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo GFF MDI (PT003), Placebo MDI, Spiriva® Respimat® (Tiotropium Bromide) - COPD | Phase 3 | Completed | Pearl Therapeutics, Inc. | 80 | 2015-02-01 | 2017-04-19 |
| 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI GFF MDI (PT003), Placebo MDI - COPD | Phase 3 | Completed | Pearl Therapeutics, Inc. | 43 | 2015-02-01 | 2018-07-19 |
| Glycopyrronium and Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) Dose Indicator Study in Adults With Moderate to Very Severe COPD Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler - COPD | Phase 3 | Completed | Pearl Therapeutics, Inc. | 138 | 2014-11-01 | 2016-12-23 |
| A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD SUN-101 50 mcg BID eFlow (CS) nebulizer, Spiriva® 18 mcg QD Handihaler - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Sunovion Respiratory Development Inc. | 1087 | 2014-10-01 | 2018-03-13 |
| Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients. NVA237, Tiotropium Respimat® - Pulmonary Disease, Chronic Obstructive | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2014-04-01 | 2016-08-22 |
Showing 20 of 46. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (35) · Asthma (2) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Respiratory Tract Diseases (2) · Burns (1) · Constipation (1) · Dyspnea (1) · Encopresis (1) · Fecal Incontinence (1) · Motor Activity (1) · Neurogenic Bowel (1) · Signs and Symptoms, Respiratory (1) · Smoking Cessation (1) · Spinal Cord Injuries (1)
Novartis Pharmaceuticals (22) · Merck Sharp & Dohme LLC (5) · Pearl Therapeutics, Inc. (5) · AstraZeneca (3) · Chiesi Farmaceutici S.p.A. (2) · Novartis (2) · Eurofarma Laboratorios S.A. (1) · James J. Peters Veterans Affairs Medical Center (1) · Mundipharma Research Limited (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Sunovion Respiratory Development Inc. (1) · University of Kansas Medical Center (1) · University of Michigan (1)
United States (23) · Hungary (11) · Canada (10) · Germany (10) · South Korea (9) · Poland (8) · Russia (8) · Spain (8) · Czechia (6) · France (6) · Philippines (6) · United Kingdom (6) · Bulgaria (5) · India (5) · Japan (5)
Colin Reisner, MD (5) · Anthony Kovac, MD (1) · Christopher P Cardozo, MD (1) · Corinne Wild, PhD (1) · Jinping Zheng (1) · Martin Brutsche, Prof. Dr. med. (1) · MeiLan Han, MD, MS (1) · Prescott Woodruff, MD, MPH (1) · Thomas Siler, MD (1)
PMID 24156566, PMID 28821260, PMID 31539467, PMID 32021148, PMID 32450869, PMID 35815359, PMID 18385265, PMID 18946293, PMID 19713265, PMID 20683334, PMID 20809967, PMID 22151296, PMID 22973092, PMID 23060624, PMID 24321804, PMID 24429126, PMID 24438744, PMID 24534204, PMID 24596459, PMID 25208233, PMID 25609942, PMID 25841237, PMID 25935840, PMID 26177074, PMID 27215502, PMID 28077140, PMID 28720336, PMID 28848879, PMID 28919143, PMID 28993871, PMID 30335559, PMID 30584583, PMID 31267366, PMID 32021143, PMID 33757520, PMID 36066078, PMID 42551404
2009 (3), 2023 (2), 2008 (1), U01HL128952 (1)